MAGENTA Study featured on KING5 Seattle.
MAGENTA Study by Turna Ray in GenomeWeb – MAGENTA Study.
Merck Catalyst Clinical Trial:
The combination of the PARP inhibitor niraparib (Tesaro) plus the checkpoint inhibitor pembrolizumab (Merck) appears to hold promise for the treatment of platinum-resistant ovarian cancer as discussed by Dream Team Investigator Panos Konstantinopoulos, MD.
  For more information
MAGENTA Clinical Trial featured on WJBK Detroit
MAGENTA Clinical Trial featured on WCCO Minneapolis
The Society of Gynecologic Oncology (SGO) Humanitarianism & Volunteerism Award

Kathleen Gavin, Executive Director of the Minnesota Ovarian Cancer Alliance (MOCA) in Minneapolis, MN, received the Gynecologic Oncology Humanitarian and Volunteerism Award, which is awarded to an individual for their exemplary local, national or international volunteer and outreach efforts in women’s cancer care, research or training. Ms. Gavin has been the executive director of MOCA since 2002 when she became its first staff person.

Established in 2012, the Gynecologic Oncology Humanitarianism & Volunteerism Award is awarded to an individual for their exemplary local, national or international volunteer and outreach efforts in women’s cancer care, research or training.

Congratulations to Karen Lu on receiving the 2018 American Cancer Society Award

WQAD News 8 story on our WISP clinical trial:
YOUR HEALTH: Fighting ovarian cancer by not removing the ovaries   (video)

The National Academy of Medicine (NAM) today announced the election of 70 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
“These newly elected members represent the most exceptional scholars and leaders in science, medicine, and health in the U.S. and around the globe,” said National Academy of Medicine President Victor J. Dzau. “Their expertise will help our organization address today’s most pressing health challenges and inform the future of health and health care to benefit us all. I am honored to welcome these distinguished individuals to the National Academy of Medicine.”
Congratulations to Alan D’Andrea upon his election to NAM!

SU2C Ovarian Cancer Dream Team Receives SU2C Catalyst® Award for Innovative Clinical Trial.

DNA repair therapies for ovarian cancer. Alan D. D’Andrea, MD, Dana-Farber Cancer Institute, and Elizabeth M. Swisher, MD, University of Washington.

Press Release
SU2C Catalyst Clinical Trials Launched

Stand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects Combining Cancer Treatments from 9 Different Pharmaceutical Companies to Explore Innovative Approaches and Find New Indications for Blockbuster Drugs from Major Companies to Improve Patient Outcomes
Medicines provided by SU2C Catalyst Charter Supporters Merck, Bristol-Myers Squibb, and Genentech are focus of unprecedented effort

PHILADELPHIA –– Stand Up To Cancer (SU2C) has awarded 10 SU2C Catalyst® clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials—with correlated translational research which will deepen our understanding of why treatments are effective—across a variety of cancers, in a program supported by industry. The inaugural SU2C Catalyst projects will explore new uses for an array of powerful medicines, from the three SU2C Catalyst Charter Supporters and six other pharmaceutical companies, the American Association for Cancer Research, SU2C’s Scientific Partner, announced today.

Grants to support the trials, as well as access to medicines, are being provided by the three Charter Supporters: founding collaborator Merck (known as MSD outside the US and Canada), as well as Bristol-Myers Squibb Company and Genentech, a member of the Roche Group. These Charter Supporters offered compounds—both new pharmaceutical compounds that they are developing, and approved agents that can be investigated for other uses—to be used by the academic cancer research community, singly or in combination with products from the Charter Supporters or other companies.  The use of these treatments and combinations with compounds from additional companies—in some cases triple combinations—were proposed by the academic research community in response to competitive Requests for Proposals. The proposals were evaluated and selected by industry-specific sub-committees, predominantly composed of leading academic scientists.

SU2C Catalyst establishes a mechanism through which industry and academic scientists in the cancer community conduct SU2C collaborative research projects to deliver benefits for patients and society. In addition to creating these opportunities for innovative collaboration, SU2C Catalyst significantly expedites the process of going from ideas to contracts to trials, compared to traditional investigator-initiated studies.

“This unique industry/academic collaboration has reduced the time for SU2C to get clinical trials started by more than 75 percent while bringing significant scientific rigor to the selection and oversight of the projects,” stated SU2C President and CEO Sung Poblete, PhD, RN. “SU2C actively manages these grants to minimize delays and support the achievement of key milestones.”

“Where companies often focus on an approval pathway for a specific indication, SU2C Catalyst broadens the approach by asking the scientific community how best to use the treatment in any setting and in any combination,” said Phillip A. Sharp, PhD, chairman of the SU2C Scientific Advisory Committee, institute professor at MIT, a member of its Koch Institute for Integrative Cancer Research, and Nobel laureate. “These SU2C Catalyst projects promote combinations that would not likely be considered without this program even before they’re approved for other indications.”

SU2C Catalyst projects also investigates why the combinations work, not just if the combinations work.

IMPACT Publications from Dream Team Members:

The Lancet:  “Rucaparib in relapsed, platinum-sensitive high-gradeovarian carcinoma (ARIEL2 Part 1): an internationalmulticentre, open-label, phase 2 trial”

Swisher_ARIEL2-Part1-LancetOncol_2016;Epub

COMMENTARY:  “Progress in PARP inhibitors beyond BRCA mutant recurrent
ovarian cancer?”

Gonzales-Martin_LancetOncol_ARIEL2-Part1-Commentary_2016;Epub

Nature Communications:  “Robust homology-directed repair within mouse
mammary tissue is not specifically affected by Brca2 mutation”

Kass et al, Nat Commun, 2016

AWARDS:

Recipient of the 2016 SU2C Phillip A. Sharp Innovation in Collaboration Award. This Award is intended to reward distinctive collaborations between senior and junior researchers that propose to accelerate current research and development models, bringing therapeutic benefits for cancer patients.

“Functional verification of DNA repair mutations in prostate and ovary tumors”
Eliezer Van Allen, MD, SU2C-Prostate Cancer Foundation Prostate Cancer Dream Team and
Maria Jasin, PhD, SU2C-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team